Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0WOBTH)
| ADC Name |
DS-3939
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
DS-3939; GT-00A ADC; DS-3939a
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
7.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Gatipotuzumab
|
Antibody Info | ||||
| Antigen Name |
Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
deruxtecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1, LVEF ≥50%, measurable disease) must provide tumor samples for MUC1 analysis; exclusions include prior MUC1 therapy, active CNS metastases, uncontrolled infections (HIV/HBV/HCV), interstitial lung disease, or thromboembolic/autoimmune disorders within 6 months.
|
||||
| Administration Dosage |
One IV infusion Q3W on Day 1 of each 21-day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05875168 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study assesses dose-limiting toxicities (DLTs) within 3 months and tracks treatment-emergent adverse events (AEs) with objective response rates over ~31 months.
|
||||
| Other Endpoint |
Efficacy is evaluated via objective response rate, disease control rate, duration of response, and survival outcomes (PFS, OS) over ~31 months, alongside pharmacokinetic (AUC, Cmax, Tmax, T1/2) and immunogenicity (anti-drug antibodies) profiling extending up to 47 months, with TA-MUC1 expression analyzed at baseline.
|
||||